Ozempic Is Making People Move Less

Miles: Hey, welcome back to Full Spectrum Fit. I'm Miles, joined as always by Amara, and we've got a spicy one for you today. Amara: Spicy is an understatement. I saw something at the gym this week that I cannot stop thinking about. Miles: Okay, I'm listening. Amara: Guy on Ozempic visibly lighter than three months ago just sitting on a bench between sets for like eight minutes not resting just done and Miles: Ohh, yeah, Amara: then get this there's brand new data out of ENDO 2026 that basically explains exactly what I watched happen happen Miles: the Endocrine Society dropped a study this week. 753 adults chalked through NIH Fitbit data. And what they've found cuts against everything people assume about weight loss driving you to move more. Amara: Plot twist! Losing weight on a GLP-1 does not make you more active. If anything, Miles: The opposite. Amara: Exactly. And we're going to look at why, because the mechanism is actually fascinating and a little unsettling if you're someone who lifts. Miles: So the agenda today, we break down the study design and what the data actually says versus what the what the headlines are claiming. Then Amara walks us through what's happening physiologically, brain reward circuits, appetite suppression, the whole picture. Amara: And we close with the practical side, muscle loss numbers, a real protocol for people already on these drugs, and what you should be tracking in the first 60 to 90 days. Miles: Spoiler, it's not just your weight. Amara: Definitely not. Okay, let's talk about what you were actually doing at the gym this week. tweak before we get into the data. Miles: Mine was humbling, honestly. Tried to PR my trap bar deadlift and got a very clear message from my hamstrings. Amara: The hamstrings always have the final word. Mine was a solid week, kept it simple, which is kind of the theme of today's episode. Miles: All right, the study just dropped and the numbers are worth slowing down on. Amara, take us in. So this week, I finally got back under the bar after that pulled lat situation. Nothing heroic, just some light deadlifts. Felt out where things were. Amara: Light deadlifts. Miles, you said that same thing right before you pulled the lat. Miles: I was very controlled this time. Completely different. Amara: Sure, sure. Miles: Howd your week look? Amara: So I had a pretty solid week, actually. Heavy squat day Thursday, tempo work Friday, but then, okay, get this. I ran into someone I hadn't seen in a few months at the gym. She's been on Wegovy since January, down like 30 pounds, looking great. And she was on a stationary bike going, I don't know, eight? Miles: Eight out of what, a hundred? Amara: I mean, maybe. And I found myself thinking, is that the drug or is she just having an off day? Miles: That's a fair question, and I've been noticing similar things. We actually covered GLP-1s before, but some new data just dropped out of ENDO. Out of ENDO-2026 that reframes this pretty significantly. Amara: Yeah. So ENDO-2026, the Endocrine Society's annual meeting in Chicago this past weekend, researchers presented a study and the numbers are not subtle. Medicalxpress and Science Daily both covered it this week. Miles: What did they find? Amara: So the team used Fitbit data from the NIH All of Us research program, actual wearable data, not self-reporting, on 753 adults with obesity. who started a GLP-1 drug. And after starting, daily step counts dropped from 5,047 to 4,487. Moderate-to-vigorous exercise fell from 28 minutes a day down to 22 minutes. Miles: Wait, they lost weight and moved less? Amara: That's the paradox. The assumption has always been lose weight, feel lighter, move more. This study found the opposite. That's it. Miles: So it's not that they can't move, they're just not. Amara: Right. And GLP-1 drugs already strip some lean muscle alongside fat. So if activity drops at the same time, you're losing muscle from two directions at once. Miles: That's a real problem for anyone in a gym right now trying to figure out what to tell a training partner who just started Ozempic. Amara: Exactly. And what nobody's explaining yet is why the drug seems to quiet down the urge to move in the- in the first place. Miles: Wow. Amara: That mechanism is the part worth pulling apart. Miles: So what is actually happening in the brain here? Sure. Okay, so let's actually look at the study design, because that's where it gets real. Amara: Yeah, exactly. What kind of data are we actually working with here? Miles: So, this is a retrospective pre-post cohort study. The researchers pulled from the NIH All of Us research program that's a database that links people's electronic health records directly to their Fitbit activity data. Real-world wearable data, not a questionnaire. Amara: That's a meaningful distinction. Most prior studies in this space use self reported activity. Miles: Healio actually quoted the lead author, Dr. Sajana Maharjan, on exactly that. She said most prior studies relied on self reported activity. This gave them wearable measured data on the same patients before and after starting therapy. Amara: So-apples to apples. Miles: Apples to apples, they started with nineteen hundred fifty adults with obesity who began a GLP-1 drug, narrowed to seven hundred fifty fifty three once they filtered for people with enough Fitbit data to actually analyze. Seventy nine percent women, average age around fifty three. Amara: Hmm, I want to poke at that a little. That's a pretty specific demographic slice: mostly middle aged women. Miles: Fair push, the authors acknowledge that the sample isn't fully representative, but the Medicalxpress write-up noted that factors like age, heart failure, and prior stroke didn't change the results. The pattern held across those variables. Amara: Okay, and this is conference data, right? Not published in a journal yet. Miles: Ken Grax presented at ENDO 2026 last weekend the Endocrine Society's annual meeting in Chicago. Preliminary findings, not a randomized controlled trial. That's worth keeping in mind. Amara: So it tells us something real is happening doesn't tell us exactly why. Miles: Right, and that's actually the more uncomfortable finding. According to Science Daily's coverage, the researchers explicitly found no evidence that weight loss from these medications led to more movement. That directly contradicts a widely held assumption. Amara: The lighter body more energy theory. Miles: Exactly that theory, which makes clinical sense on paper. You lose thirty pounds, stairs get easier, you move more. That's the expected direction. Amara: But the data went the other way. Miles: The data went the other way. And, according to Medicalxpress, the largest declines showed up in men and in people with existing joint or muscle pain. Wait—men declined more? The cohort was almost seventy-nine per cent women. Amara: Right, so men were a smaller subgroup, but showed steeper drops proportionally. The joint and muscle pain piece makes some intuitive sense—if the drug suppresses appetite enough. Miles: Not that you're eating significantly less, fatigue is a real side effect, and people already dealing with pain are probably the first to stop pushing through it. Amara: I've seen this play out a hundred times with clients cutting calories hard. The body starts rationing effort. Miles: Which is probably pointing at something neurological, not just mechanical, and the study authors specifically called for structured exercise counseling at the time of drug initiation not as a lifestyle tip, but as part of the prescription protocol. Amara: That's a significant ask. Most prescribers aren't exercise physiologists. Miles: No, they're not, which is a real gap. And it raises the bigger question, is what we're seeing here a GLP-1 specific effect on the brain's motivation systems? Or is it just what happens when caloric intake drops sharply on any intervention? Amara: Actually, that's where the physiology gets fascinating because these drugs don't just work in the gut. Miles: They don't, and that might explain a lot more than the numbers alone. Just alone can show us. Amara: So flip it around from the data. The study tells us what's happening, but why? Miles: And this is where the neuroscience actually gets interesting. GLP-1 receptors aren't just in your gut, Amara: Wow. Miles: they're in your brain, specifically in regions tied to reward and motivation. Amara: Dopamine territory. Miles: Exactly. Neuroscience News covered research showing the drug's influence on a pathway connecting the hindbrain, the central amygdala, and dopamine-producing neurons. The whole circuit that drives you to want things—food, movement, motivation broadly. Amara: So it's not just that you're less hungry, your brain's drive to go get something is turned down. Miles: That's the working theory, and there's a separate layer on top of that: NEAT, non-exercise activity thermogenesis—your fidgeting, your pacing, the way some people just can't sit still. Amara: Right, the stuff that burns calories without feeling like exercise. Miles: When calories drop sharply, the body pulls back on that. That spontaneous movement as an energy conservation response, it's pretty well documented in caloric restriction research, not GLP-1 specific. Amara: And that's actually where I push back a little. I've coached people running steep deficits the old-fashioned way, just eating less, and they lose motivation to train too, dragging themselves to the gym, skipping sessions. Is this a drug effect or just a big deficit? Miles: Both, but speed matters. GLP-1s can cut cut intake dramatically fast. We're not talking about someone grinding through a modest five hundred calorie daily deficit over months. Some people on these drugs are essentially in semi starvation territory for an extended period without feeling it. Amara: Because the hunger signal is gone. Miles: Gone or very quiet. And clinically, fatigue during active weight loss is one of the most commonly reported experiences on these medications. Exercise feels harder than it actually is. So you've got the brain's motivation circuits quieted, NEAT suppressed by the deficit, and then fatigue making planned workouts feel like a mountain. Amara: So three different things all pointing in the same direction: down. Miles: Three compounding mechanisms, and the Neuroscience News piece specifically called this a behavioral paradox. You're losing weight but becoming less active in the process. Amara: Which is the opposite of what most people expect lighter body, more energy, right? Miles: That's the assumption. The data from ENDO 2026 says otherwise. Amara: So the drug quiets the brain's reward circuitry, the deficit suppresses the low-level background movement, and fatigue kills the gym sessions. And underneath all of that, Miles: The muscle is sitting there unprotected. Amara: which is exactly what we need to get into. Because if motivation drops and training drops with it, what does that actually cost you in lean mass? The numbers on that are not... not comfortable Miles: No, they're not; that's the next piece. Amara: So the muscle loss risk, that's where the real alarm is. Training drops, caloric deficit deepens, and the body starts cannibalizing lean mass. Miles: And the numbers are not small. The American Diabetes Association has published figures showing lean body mass can account for anywhere from 15 to 40% of total weight lost on GLP-1 therapy. That's a wide range, but even the low end of that range is significant. Amara: I've seen this play out with someone I trained with. Lost thirty some pounds on Cymopatide. Looked lighter, felt lighter, but his squat numbers cratered. Strength just gone. Miles: And that's exactly what the research predicts. Less movement, deep caloric deficit, and no intentional resistance work. You're going to lose muscle. That's not the drug being uniquely evil. Any big deficit does that. The drug just makes the deficit. bit bigger and easier to sustain. Amara: Which means the fix is obvious in theory. Miles: Right, lift weights. Amara: Lift weights. But let's get specific, because just lift is not a protocol. From what the evidence shows, and I want to be clear, most of this is extrapolated from general weight loss research, not GLP-1-specific trials. Two to three sessions a week of resistance training targeting major muscle groups shows meaningful lean mass retention. Miles: The LEAN-PREP trial is actually trying to fill that gap. It's currently enrolling, published as a protocol in BMJ Open in April, and it'll be the first proper randomized controlled trial testing resistance training specifically against GLP-1-induced lean mass loss, so we're still waiting for that drug-specific data. Amara: Which means right now, every recommendation you hear is the best educated guess we have. I want people to know that. that going in. Miles: Honest caveat and a necessary one. Amara: So what does the gym actually look like? Compound movements like squats, deadlifts, rows, presses, things that recruit the most muscle per set. Progressive overload, meaning you're adding weight or reps over time, not just showing up and going through the motions. Miles: And frequency matters more than any single session being perfect. Two solid sessions a week is better than one brutal one you can't. One you can't recover from, especially when your caloric intake is already suppressed. Amara: That's the real trap I see. Someone on Ozempic is eating maybe 1,200, 1,300 calories. They try to train hard and eat like a bird and recovery just doesn't happen. Miles: Which brings us to protein. The evidence clusters around 1.2 to 1.6 grams per kilogram of body weight per day and critically spread across meals. Not front or back loaded into one sitting, leucine-rich sources get priority—eggs, chicken, Greek yogurt, cottage cheese. Amara: Getting to 1.6 grams per kilo when you're barely hungry is, I'm not going to lie, that's legitimately hard. Miles: Which is the drug that's suppressing your appetite is also making it harder to eat enough protein to protect your muscle. So that's fun. Amara: Yeah, I love that. Miles: It's a whole thing, but it's solvable. Protein shakes, prioritizing protein at the start of every meal before appetite disappears, tracking for a few weeks just to know where you actually land. Amara: And this connects directly to what we want to talk about next because all of this is really a monitoring conversation. If you're on a GLP-1 drug and you're already training, you might assume you're fine, but the data says even active people can drift. Miles: Catching that drift early is what matters most for someone who wants to protect what they've built. Amara: So if you train already, you're logging sessions, you're eating with intention, does any of this actually apply to you? Miles: Honestly, yes. Not because you're likely to become sedentary, but because drift is subtle. You don't notice it until you're down 20% on your step count and wondering why your lips feel heavier. Amara: I've seen that exact thing. Someone's numbers look fine on paper, training three days a week, but their total daily movement has quietly dropped. dropped: NEAT, the steps, the fidgeting, the walking to the car-just gone. Miles: And Neuroscience News covered the researchers' specific recommendation on this: remote wearable tracking from day one, not as a nice to have, as part of the clinical prescription. Amara: Which honestly makes sense. You track your lifts, you track your macros, why wouldn't you track Miles: Right. Amara: daily movement during the first sixty to ninety days? Miles: That window matters. The Fitbit data showed the drop happens early. If you're watching the numbers, you catch it before you feel it. Amara: One thing I'd tell a client, treat your step floor like you treat your training minimum. If you're normally hitting nine or ten thousand steps and you're suddenly seeing six, that's data. That's not a rest day. That's drift. Miles: And from a research standpoint, the thing I'd flag is that the drug isn't failing your body's reward response to movement is just quieter right now. You may need to schedule activity you used to Amara: do Yeah. Miles: automatically. Amara: Intentional where it used to be instinctive Miles: Exactly; the wearable doesn't fix it, but it makes the invisible visible before it becomes a real problem. Amara: That's the part most active people don't see coming, and honestly it's the question I'm still sitting with. All right, that's a wrap on a big one Miles: And it started because I spotted someone on a stationary bike going nowhere physically and metaphorically. Amara: Right, right. And that one gym observation cracked open the whole episode. The Endo 2026 data confirmed it. People on GLP-1s are moving less, not more, even as the weight drops. Miles: And the muscle loss piece is what I keep coming back to. Losing lean mass from two directions at once, that's the part that should change how clinicians prescribe these drugs. Amara: Exactly. If you're on a GLP-1 or know someone who is, watch the wearable data in those first 60 to 90 days. Your step count is a training metric now. Miles: Treat it like one. Amara: If this episode made you look at your own movement habits differently, drop us a review or tag us at Full Spectrum Fit. New episodes every Tuesday. Miles: Thanks for being here. Go lift something heavy, on purpose this time.